PICCOLO: final analysis of mirvetuximab soravtansine in ovarian cancer

19 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Angeles Secord, MD, Duke Cancer Institute, Durham, NC, discusses the final analysis of the Phase II PICCOLO study (NCT05041257), which assessed mirvetuximab soravtansine in folate receptor alpha (FRα)-positive platinum-sensitive ovarian cancer. The treatment demonstrated durable responses and encouraging survival outcomes, including in patients with prior progression on PARP inhibitors. The safety profile remained consistent with earlier findings, with no new adverse events reported. This interview took place at 2025 European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo